EMAIL THIS PAGE TO A FRIEND

Oncotarget

Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.


PMID 26506422

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis in various types of cancer cells without damaging normal cells. However, in terms of pancreatic cancer, not all cancer cells are sensitive to TRAIL. In this study, we examined a panel of human pancreatic cancer cell lines for TRAIL sensitivity and investigated the effects of Bcl-2 family inhibitors on their response to TRAIL. Both ABT-263 and ABT-737 inhibited the function of Bcl-2, Bcl-xL, and Bcl-w. Of the nine pancreatic cancer cell lines tested, six showed no or low sensitivity to TRAIL, which correlated with protein expression of Bcl-xL. ABT-263 significantly sensitized four cell lines (AsPC-1, Panc-1, CFPAC-1, and Panc10.05) to TRAIL, with reduced cell viability and increased apoptosis. Knockdown of Bcl-xL, but not Bcl-2, by siRNA transfection increased the sensitivity of AsPC-1 and Panc-1 cells to TRAIL. ABT-263 treatment had no effect on protein expression of Bcl-2, Bcl-xL, or c-FLIPs. In Panc-1 cells, ABT-263 increased the surface expression of death receptor (DR) 5; the NF-κB pathway, but not endoplasmic reticulum stress, participated in the increase. In xenograft mouse models, the combination of TRAIL and ATB-737 suppressed the in vivo tumor growth of AsPC-1 and Panc-1 cells. These results indicate that Bcl-xL is responsible for TRAIL resistance in human pancreatic cancer cells, and that Bcl-2 family inhibitors could represent promising reagents to sensitize human pancreatic cancers in DR-targeting therapy.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1405706
Anti-DDIT3 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB3500428
Anti-DR4 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
D3938
Anti-DR5 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB3500427
Anti-DR5 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB4500632
Anti-GADD153 antibody produced in rabbit, affinity isolated antibody
AV02065
Anti-TNFRSF10A antibody produced in rabbit, IgG fraction of antiserum
HPA054475
Anti-TNFRSF10A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1406725
Anti-TNFRSF10B antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA023625
Anti-TNFRSF10B antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2102489
Anti-TNFRSF10B antibody produced in rabbit, affinity isolated antibody
EHU087041 MISSION® esiRNA, esiRNA human BCL2L1 (esiRNA1)
EMU088941 MISSION® esiRNA, esiRNA targeting mouse Bcl2l1 (esiRNA1)
SAB4700538 Monoclonal Anti-CD262 antibody produced in mouse, clone DR5-01-1, purified immunoglobulin, buffered aqueous solution
WH0001649M1
Monoclonal Anti-DDIT3 antibody produced in mouse, clone 2G3, purified immunoglobulin, buffered aqueous solution
SAB1403729
Monoclonal Anti-DDIT3 antibody produced in mouse, clone 2C4, purified immunoglobulin, buffered aqueous solution
WH0008797M1
Monoclonal Anti-TNFRSF10A antibody produced in mouse, clone 2E8, purified immunoglobulin, buffered aqueous solution
SAB1404626
Monoclonal Anti-TNFRSF10A antibody produced in mouse, clone 2E9, purified immunoglobulin, buffered aqueous solution
WH0008795M1
Monoclonal Anti-TNFRSF10B antibody produced in mouse, clone 2D6, purified immunoglobulin, buffered aqueous solution
C1230
Z-Ile-Glu(O-ME)-Thr-Asp(O-Me) fluoromethyl ketone, ≥90% (TLC), powder
C30H43FN4O11
C1355
Z-Leu-Glu(O-Me)-His-Asp(O-Me) fluoromethyl ketone trifluoroacetate salt hydrate, ≥90%
C32H43FN6O10 · xC2HF3O2 · yH2O